Beijing Jiu He Pharmaceutical Ltd.

Primary objective: To compare the differences in the extent and rate of absorption of bilastine oral solution (120 mL: 0.3 g) provided by Beijing Yuanda Jiuhe Pharmaceutical Co., Ltd. and bilastine tablets (20 mg) licensed by Menarini International Operations Luxembourg S.A. in healthy Chinese population under fasting conditions. Secondary objective: To evaluate the safety of bilastine oral solution (120 mL: 0.3 g) provided by Beijing Yuanda Jiuhe Pharmaceutical Co., Ltd. and bilastine tablets (20 mg) licensed by Menarini International Operations Luxembourg S.A. in healthy study participants under fasting conditions. To evaluate the palatability of bilastine oral solution in healthy Chinese population and provide a basis for the taste of bilastine oral solution.

Primary objective: To evaluate the safety and tolerability of single and multiple oral doses of GPN00204 in healthy adult subjects in China. Secondary objectives: To evaluate the pharmacokinetic (PK) characteristics of single and multiple oral doses of GPN00204 in healthy adult subjects in China, and to compare the PK parameters of each component with those of single and multiple oral doses of eucalyptol enteric-coated capsules (Cenox®, 0.3g); to evaluate the effect of food on the pharmacokinetics of GPN00204.

Primary objective: To evaluate the safety and tolerability of a single dose of Eucalyptus, Lemon and Pinus Soft Capsules in healthy Chinese adult subjects. Secondary objective: To evaluate the pharmacokinetic (PK) characteristics of the test drug (modified formulation, Eucalyptus, Lemon and Pinus Soft Capsules) in healthy Chinese adult subjects after a single dose; to compare the differences in pharmacokinetic (PK) characteristics between the test drug (modified formulation, Eucalyptus, Lemon and Pinus Soft Capsules) and the control drug (original formulation, Eucalyptus, Lemon and Pinus Enteric-coated Capsules Cherno®).